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Immunological mechanisms and therapy approaches in psychotic syndromes were
recently supported by the discovery of autoantibody-associated limbic and non-limbic
encephalitis. However, how clinical diagnostic procedures in psychiatry should be
adapted to these new insights is still unclear. In this study, we analyzed the cerebrospinal
fluid (CSF) and neuroimmunological alterations and their association with cerebral MRI
(cMRI) and electroencephalographic (EEG) findings. From 2006 to 2013, we acquired
180 CSF samples from psychotic patients. Between 2006 and 2009, CSF examinations
were only performed in cases in which organic brain disease was suspected. Since
then, this procedure has been integrated into our routine diagnostic workup. CSF
basic diagnostics were supplemented by measuring antineuronal antibodies against
intracellular synaptic antigens, antibodies against intracellular onconeural antigens,
antibodies against neuronal cell surface antigens and thyroid antibodies. In addition,
cMRIs and EEGs were conducted. We found white cell counts elevated in 3.4% of
the cases, albumin quotient elevated in 21.8%, and protein concentration elevated in
42.2%. Evidence of intrathecal immunoglobulin synthesis was found in 7.2% of the
cases. Antibodies measured against neuronal cell surface antigens were positive in 3.2%.
Reactivity on antibodies against intracellular onconeural antigens were detected in 3.5%.
Serum thyroid antibodies were elevated in 24.7%. Abnormalities were found in 39.5%
of cMRIs and in 34.3% of EEGs. The main finding of our study was the high prevalence
of CSF and autoantibody abnormalities in 54.4% of psychotic patients. In combination
with cMRIs and EEGs, 75.6% showed abnormal findings. Our results are discussed with
regard to the concept of immunological encephalopathy. Future studies should analyze
the efficacy of immunomodulatory therapies.
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Introduction
Psychosis was identiﬁed as a possible immunological disease as early as 1930 in the work
of Lehmann-Facius among others. He described a highly speciﬁc method called “brain–lipoid
reaction” to detect immunological signals in psychotic patients. This in turn led to the autoimmune
hypothesis of schizophrenia (Roeder, 1939). Immunological concepts were recently supported
Endres et al. Immunological findings in psychoses
by autoantibody-associated limbic and non-limbic encephalitis
dissembling psychotic syndromes. In this context, antineuronal
antibodies against intracellular synaptic antigens, intracellular
onconeural antigens, and neuronal cell surface antigens could
be distinguished. Neuronal cell surface antigens appear to be
particularly associated with psychotic symptoms (Prüss et al.,
2010; Dalmau et al., 2011; Vincent et al., 2011). Moreover,
steroid responsive encephalopathy associated with autoimmune
thyroiditis (SREAT) has received an increased level of interest in
recent years because it was identiﬁed as the cause for classical
psychotic and aﬀective disorders in several cases (Castillo et al.,
2006).
Role of Cerebrospinal Fluid (CSF) Analysis in
Clinical Diagnostics of Psychotic Patients
Cerebrospinal ﬂuid (CSF) investigation is the most precise
method of detecting and characterizing central nervous system
inﬂammatory processes, even when cerebral magnetic resonance
imaging (cMRI) or electroencephalographic (EEG) results are
normal. In most guidelines (e.g., Nice guidelines, http://www.
nice.org.uk; German S3-Praxisleitlinie, www.dgppn.de), CSF
examinations are not recommended in the diagnostic routine
work up of psychotic or aﬀective disorders. However, there
have been several recent reports pointing to good response
to immune therapy in patients with classical psychiatric
manifestations of psychotic or aﬀective disorder without organic
symptoms or signs (van Elst et al., 2011; Chang et al.,
2013). These observations put the psychiatric clinician in
a diﬃcult position because it is hard to judge when to
initiate and when to leave CSF analyses in an individual
case.
Rationale of Our Study
At the university clinic of psychiatry and psychotherapy
Freiburg, traditionally CSF studies have always been done in
case of psychotic patients if there were any signs pointing
to possible neuroinﬂammatory features, such as atypical and
sudden-onsets, seizures, or suspicious cMRI/EEG ﬁndings.
Following own experiences with patients with limbic encephalitis
presenting like schizophreniform syndromes, since June 2009,
we oﬀered CSF analyses as part of our routine work up
to all psychotic patients who were admitted for diagnostic
purposes. With these data at hand, the aim of this retrospective
study was threefold. (1) We wanted to investigate the
frequency of CSF and neuroimmunological alterations and
their association with cMRI and EEG ﬁndings in psychotic
syndromes. We hypothesized to ﬁnd increased prevalences
of CSF-basic laboratory abnormalities and autoantibody rates
in psychotic patients as well as an association between CSF
and cMRI/EEG abnormalities. (2) We wanted to analyze how
a change in diagnostic approach might aﬀect the respective
immunological ﬁndings. Could it be that our new diagnostic
approach to oﬀer CSF studies to all psychotic subjects is
excessive and produces lots of negative ﬁndings? (3) We wanted
to analyze on a case by case level, whether the ﬁndings of
immunological signals have therapeutic implications for our
patients.
Participants and Methods
The study received approval from the local ethics committee of
the University of Freiburg (EK-Fr 609/14). All patients included
gave written informed consent for CSF studies during the clinical
diagnostic work up.
CSF Collective
From 2006 to October 2013, we acquired 180 CSF samples from
psychotic patients at the Clinic of Psychiatry and Psychotherapy
of Freiburg University Hospital. Lumbar punctures (LPs) were
generally performed during the initial manifestation of psychotic
symptoms. Three clinically deﬁned subgroups were analyzed:
(1) patients with a schizophreniform syndrome, (2) patients
with a schizoaﬀective syndrome, and (3) patients with psychotic
syndromes in the context of other disorders (Table 1).
Measurement Protocols
From 2006 to June 2009, we obtained 34 CSF analyses following
the traditional approach i.e., LP was done only if there were
speciﬁc symptoms and signs pointing to an organic cause of
psychotic symptoms. This corresponds to 9.7 LPs per year. Since
June 2009, we have introduced LP as a standard procedure in all
psychotic patients with acute de novo psychotic symptoms under
our care. We measured 146 cases until October 2013 (34.4 LPs
per year).
Immunological assessment
In all cases, paired CSF and serum samples were taken at
the same time. CSF diagnostics were performed in the CSF
laboratory of the Department of Neurology. CSF white blood
count (WBC) and cytological diﬀerentiation of CSF sediment
were established with manual microscopy (Leica DMRB,
Germany) using a Fuchs-Rosenthal counting chamber (Hecht-
Assistant, Germany). Basic quantitative protein diagnostics
included total CSF protein concentration, albumin, and Ig
G, M, and A concentrations in CSF and serum, respectively
(ProSpect System, Siemens, Erlangen, Germany). For detection
of a blood–brain barrier (BBB) dysfunction, we calculated the
age-related albumin quotient since this marker is accepted
as the “gold standard” for the estimation of the integrity
of the BBB (Reiber and Peter, 2001). For determination
of oligoclonal bands (OCBs), we used isoelectric focusing
followed by immunoﬁxation (Hydragel Isofocusing, Sebia,
France). Intrathecal Ig synthesis was considered signiﬁcant if
intrathecal Ig fraction-values exceeded 10% in the “Reibergram”-
analysis (Reiber and Peter, 2001) and/or if OCBs were
present exclusively or predominantly in CSF according to
the criteria of the European experts’ consensus (Andersson
et al., 1994). A commercially available immunoblot employing
recombinant neuronal antigens as the substrate (Yo, Hu, Ri,
Cv2/CRMP5, Ma1, Ma2, SOX1, amphiphysin, and GAD) was
used for qualitative detection of antineuronal antibodies against
onconeural intracellular or synaptic antigens (ravo Diagnostika,
Freiburg, Germany), as has been the case since 2006. CSF
antibodies against neuronal cell surface antigens (NMDAR,
AMPA-1/2-R, GABA-B-R, and VGKC-complex [LGI1, Caspr2])
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TABLE 1 | Subgroup classification and available number of data sets.
Psychotic CSF-collective Number of patients
(1) Schizophreniform syndrome group 132
Schizophrenia 104
Delusional disorder 4
Acute polymorphic psychotic disorder 18
Schizotypal disorder 2
Substance-induced psychosis 4
(2) Schizoaffective syndrome group 43
(3) Psychotic syndromes in the context of other disorders 5*
Diagnostic measurements Number of samples
CSF basic diagnostics (white blood cell count, protein concentration, albumin quotient, and intrathecal
immunoglobulin synthesis)
180
Intracellular synaptic antigens (GAD, amphiphysin) and intracellular onconeural antigens (Yo, Hu, Ri,
Cv2/CRMP5, Ma1, Ma2, SOX1)
142
Antibodies against neuronal cell surface antigens (NMDAR, AMPA-1/2-R, GABA-B-R, VGKC-complex) 96 (Freiburg) + 29** (Weatherall Institute of
Molecular Medicine at the John Radcliffe
Hospital [Oxford, United Kingdom])
Thyroid-antibodies
Anti-thyroid peroxidase antibodies 73
Anti-thyroglobulin antibodies 70
Thyroid-stimulating hormone receptor antibodies 33
Electroencephalography data sets 175
Magnetic resonance imaging data sets 152
*Psychotic syndrome group in the context of other disorders is consisting of (1) Morbus Wilson, (2) presumed viral encephalitis, (3) prodromal symptoms of derealization and
depersonalization, (4) prodromal symptoms within the framework of autistic spectrum disorder, and (5) acute state of confusion with psychotic symptoms. **Only NMDAR and VGKC-
complex antibodies. GAD, glutamic acid decarboxylase; Yo/ Hu/ Ri, abbreviations of first patients’ name; Cv2/CRMP5, anti-collapsin response-mediator protein; Ma1/ Ma2, 37 and
40 kDa neuronal proteins; SOX1, sry-like high-mobility group box 1; NMDAR, N-methyl-D-aspartat-receptor; AMPA-1/2-R, α-Amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
receptor; GABA-B-R, γ -aminobutyric acid receptor; VGKC-complex, voltage gated potassium channels complex.
were detected using a monospeciﬁc cell-based (transfected
HEK cells) indirect immunoﬂuorescence assay (Euroimmun,
Luebeck, Germany), as has been the case since 2011. Prior
to this, samples were sent to the reference laboratory at
the Weatherall Institute of Molecular Medicine at the John
Radcliﬀe Hospital (Oxford, United Kingdom) for measuring the
serum anti-voltage gated potassium channel (VGKC) complex
and anti-N-methyl-D-aspartat-receptor (NMDAR) antibodies.
Serum thyroid autoantibodies, including anti-thyroid peroxidase,
anti-thyroglobulin, and thyroid-stimulating hormone receptor
antibodies, were assessed only in cases of clinical suspicion
of thyroid disorder (i.e., abnormalities in thyroid hormones)
using electrochemiluminescence immunoassay tests (Roche,
Basel, Switzerland). The cMRI and EEG datasets were obtained
from clinical records; EEGs were analyzed visually by in-house
physicians, while cMRI datasets were analyzed by experienced
senior neuroradiologists. Table 1 provides an overview of the
number of datasets.
Data Handling and Statistical Analysis
All laboratory data, clinical information and cMRI and EEG
datasets were carefully researched and entered into a data
bank (SPSS 20, Statistical Package for the Social Sciences).
Mainly, descriptive statistics were calculated for the psychotic
patient group. For group comparison (respective age) between
patients with and without clear-cut antibody abnormalities,
we used a Mann–Whitney U-test. Moreover, we performed
Pearson correlation for correlation analyses between age and CSF
markers.
Results
Demographic Data
Of the 180 examined psychotic patients, 101 were female and 79
were male; the mean age was 34.67 (standard deviation ±14.7)
years.
CSF Basic Diagnostics and Immunological
Findings
Table 2A summarizes the basic CSF ﬁndings. Overall, 3.4% of
our psychotic patients displayed increasedWBC counts. Seventy-
six of the 180 patients or 42.2 % showed an increased protein
concentration, 39 patients or 21.8% showed an increased albumin
quotient and in 13 patients or 7.2% there were OCBs. Age
signiﬁcantly correlated with the protein concentration (r =
0.185, p = 0.013,N = 180) and the albumin quotient (r = 0.250,
p = 0.001, N = 179). There was no signiﬁcant correlation
between age and WBC (r = −0.068, p = 0.368, N = 179) or
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age and IgG-index (r = −0.047, p = 0.534, N = 180). Table 2B
illustrates the speciﬁc ﬁndings with respect to antineuronal
antibodies. In 4 cases or 3.2% we found antibodies against
neuronal cell surface antigens. Antibodies against intracellular
onconeural antigens were found in 5 cases or 3.5%. Thyroid-
stimulating hormone receptor antibodies were increased in 3.1%
of investigated cases, thyroid peroxidase antibodies in 17.8% and
thyroglobulin antibodies in 15.7%.
Table 3 speciﬁes all clinical relevant ﬁndings of the antibody
positive patients. Three of the nine patients with antineural
antibodies displayed clear cut additional neurological symptoms
(epileptic seizures) in addition to the schizophreniform or
schizoaﬀective syndrome earlier or later in the course of the
disease. This was not the case in the other 6 patients. The EEGwas
abnormal in 4 of 9 patients. The cMRI was completely normal
in 4 of 9 cases. However, the abnormalities in the remaining 5
of 9 were unspeciﬁc with focal atrophy being the most common
ﬁnding. An FDG-PET was done in 4 of 9 patients with mixed
results.
Patients with clear-cut antibody ﬁndings (n = 9) were
younger on average compared with antibody negative patients
(n = 171), however, these diﬀerences were not signiﬁcant
(28.78± 12.26 vs. 34.98± 14.77; U = 993.5, p = 0.142).
Effect of Diagnostic Protocol on Findings
To analyze how the introduction of a new diagnostic protocol
may aﬀect respective results, we compared the cohort obtained
between 2006 and June 2009 to the one obtained from data
since 2009. Table 4 summarizes respective ﬁndings. It illustrates
that the introduction of routine CSF studies in 2009 led to a
lower detection rate of increased WBC counts from 9.1 to 2.1%.
In contrast, the high detection rate of protein abnormalities
(increased protein concentration: 47.1% down to 41.1%; albumin
quotient: 23.5% down to 21.4%) and intrathecal immunoglobulin
synthesis (8.8% down to 6.8%) was not altered in a relevant way
and was very high even in routine assessment of CSF in psychotic
patients.
cMRI and EEG
cMRI abnormalities were detected in 39.5% of the cases (60 of
152). Of the available 175 EEG datasets, 60 showed pathological
abnormalities (34.3%). Intermittent generalized slow activity was
found most frequently (18.3%; Table 5).
Overall Abnormalities
CSF and serum analyses (including antineuronal and anti-
thyroid antibodies) showed abnormalities in 98 of the 180 cases
(54.4%). cMRI or EEG abnormalities were found in 91 of the 180
psychotic patients (50.6%). Total abnormalities in CSF analysis
and cMRI/EEG analysis were detected in 136 of the 180 cases
(75.6%).
Discussion
The main ﬁnding of our study was the high percentage of CSF
and autoantibody abnormalities in 54.4% of all psychotic patients
and overall organic abnormalities (including cMRI and EEG) in
75.6%. Before discussing the possible relevance of these ﬁndings,
we have to stress the shortcomings of our open study.
Limitations
The entire study is open and followed clinical practice. Therefore,
while the ecological validity might be high, the sample was
generated in a very unsystematic way. The total collective
includes a group of patients with suspected organic brain
disease identiﬁed between 2006 and 2009 and a more systematic
screening group since 2009. This includes all psychotic patients
who gave their written consent for LP. While the majority of
patients agreed to all proposed diagnostic procedures could not
clarify retrospectively how many patients rejected CSF studies.
Therefore, this sample cannot be regarded as representative. Still,
since this issue is rather new to psychiatry, it is diﬃcult to obtain
data frommore systematic samples. To our knowledge, this is the
ﬁrst study published in the literature looking at a large clinical
sample of unselected consecutively diagnosed psychotic patients
who were comprehensively investigated using CSF analysis,
the measurement of diﬀerent neuroimmunological markers
(autoantibodies), EEG and cMRI. The major shortcoming of
this study is the fact that we did not analyze a control
group for comparison. However, this is an open clinical
observational study, and for ethical reasons, we would not
have obtained approval for doing LPs in healthy controls
from our ethics committee, due to possible complications. The
high rates of organic pathologies might also be inﬂuenced by
medication eﬀects, comorbidities, or patient history (e.g., EEG
ﬁndings are very sensitive for such inﬂuencing factors). In
spite of these limitations, we feel that this study is of clinical
signiﬁcance because we were able to collect a large sample of
psychotic patients, who were diagnosed by experienced senior
psychiatrists in a tertiary care hospital on a strictly clinical
basis. Presently CSF studies do not belong to the recommended
diagnostic procedures. However, given the good therapeutic
response to immunomodulatory therapies in some patients
with immunological encephalopathy the issue of whether these
recommendations should be modiﬁed and adapted to the latest
ﬁndings in neuroimmunology is of obvious clinical relevance.
The Effect of More Elaborated Diagnostic
Procedures
One might have hypothesized that the change in diagnostic
protocol, essentially introducing CSF examination as a routine
diagnostic measure, would result in a majority of negative
ﬁndings. This, however, was not the case. While the prevalence of
elevated CSF WBC count went down from 9.1 to 2.1%, the same
was not true for all other global CSF basic signals. In particular,
we found strong evidence pointing to disturbed BBB function in
psychotic patients.
Role of CSF Basic Diagnostics in Psychotic
Syndromes
Several studies analyzing CSF in schizophrenia have reported
diﬀerences, especially in BBB function. Most previous studies are
older, and therefore, were assessed under diﬀerent environmental
and technical frameworks (Supplemental Table 1).
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TABLE 4 | CSF-basic diagnostics sorted by date (2006–2009: LP in suspicious cases; 2009–2013: LP as a standard screening procedure) and patient
subgroups.
Date Threshold Schizophreniform
syndrome
(N = 132)
Schizoaffective
syndrome
(N = 43)
Psychotic syndromes in
the context of other
disorders (N = 5)
Whole group of
psychotic syndrome
(N = 180)
White blood cell count* 2006–2009 <5 cells
≥5 cells
24/25 (96%)
1/25 (4%)
6/7 (85.7%)
1/7 (14.3%)
0/1 (0%)
1/1 (100%)
30/33 (90.9%)
3/33 (9.1%)
2009–2013 <5 cells
≥5 cells
105/107 (98.1%)
2/107 (1.9%)
34/35 (97.1%)
1/35 (2.9%)
4/4 (100%)
0/4 (0%)
143/146 (97.9%)
3/146 (2.1%)
Protein concentration 2006–2009 <450 mg/l
≥450 mg/l
14/25 (56%)
11/25 (44%)
4/8 (50%)
4/8 (50%)
0/1 (0%)
1/1 (100%)
18/34 (52.9%)
16/34 (47.1%)
2009–2013 <450 mg/l
≥450 mg/l
63/107 (58.9%)
44/107 (41.1%)
20/35 (57.1%)
15/35 (42.9%)
3/4 (75%)
1/4 (25%)
86/146 (58.9%)
60/146 (41.1%)
Albumin quotient* 2006–2009 Age-dependent:
Increased:
19/25 (76%)
6/25 (24%)
6/8 (75%)
2/8 (25%)
1/1 (100%)
0/1 (0%)
26/34 (76.5%)
8/34 (23.5%)
2009–2013 Age dependent:
Increased:
83/106 (78.3%)
23/106 (21.7%)
28/35 (80%)
7/35 (20%)
3/4 (75%)
1/4 (25%)
114/145 (78.6%)
31/145 (21.4%)
Intrathecal immuno-
globulin-synthesis
2006–2009 No:
Yes:
24/25 (96%)
1/25 (4%)
7/8 (87.5%)
1/8 (12.5%)
0/1 (0%)
1/1 (100%)
31/34 (91.2%)
3/34 (8.8%)
2009–2013 No:
Yes:
100/107 (93.5%)
7/107 (6.5%)
32/35 (91.4%)
3/35 (8.6%)
4/4 (100%)
0/4 (0%)
136/146 (93.2%)
10/146 (6.8%)
*Measured only in 179 of 180 samples.
WBC Count
In earlier studies, WBC count showed no abnormalities overall
in psychotic patients (Vasic et al., 2012). However, in acutely
psychotic patients, there were reports of higher rates of activated
lymphoid cells and mononuclear phagocytes, which might be
indicative of microglial activation, which—according to some
reports—normalizes over the course of the disease (Nikkilä et al.,
1999, 2001). In our sample, we found elevated WBC counts in
3.4%, which might be evidence of discrete acute autoimmune
or infectious inﬂammatory processes in a small subgroup of
psychotic patients.
BBB
Increased BBB permeability with elevated protein concentration
and CSF-to-serum albumin quotients have been described in
previous studies (Vasic et al., 2012). Bechter et al. for example,
reported a moderate BBB dysfunction in 29% of treatment-
resistant aﬀective and schizophrenic spectrum disorder patients
(Bechter et al., 2010). In particular, albumin, which is produced
only in the liver, is accepted to be the “gold standard”
for detecting BBB permeability by measuring the serum/CSF
quotient (Reiber and Peter, 2001; Vasic et al., 2012). Following
older neurophysiological models, a high albumin quotient was
interpreted as a “leakage” of BBB. Recent concepts have also
discussed a reduced CSF ﬂow caused by low CSF production
rate, increased ﬂow resistance in the subarachnoid space, or
reduced outﬂow into venous blood via the arachnoid villi as
further causal mechanisms (Reiber, 1994). In our study, we
found increased protein concentrations in 42.2% of our patients
and an elevated albumin quotient in 21.8%. While several case
studies illustrate that immunomodulatory therapy may produce
very positive results in single cases, it is not yet clear whether
evidence for BBB dysfunction should trigger therapy courses
(e.g., with steroids). Future research will have to answer this
question.
Intrathecal Immunoglobulin Synthesis
We found an intrathecal humoral immune response, indicating
chronic CSF inﬂammation, in 7.2% of our patients. Due to the
chronic and relapsing character of schizophrenia, which is similar
to multiple sclerosis, a chronic low-level central nervous system
inﬂammation in a subgroup of psychotic patients was postulated
by some authors (Bechter et al., 2010). For example, Bechter
postulated the mild encephalitis hypothesis for schizophrenia
at least for subgroups of schizophreniform patients (Bechter,
2013). Findings of intrathecal immunoglobulin synthesis may
support such notions at least for a small subgroup of psychotic
patients.
Antibodies against Neuronal Cell Surface
Antigens
Antibodies against neuronal cell surface antigens are particularly
associated with psychotic syndromes. Table 2 includes an
overview of established autoantibodies and associated
neuropsychiatric syndromes. Anti-N-methyl-D-aspartat-
receptor (NMDA-R) encephalitis for example begins mainly
with an unspeciﬁc prodromal period, which is characterized
by headache and fever and followed by a psychiatric period
of anxiety, paranoia, delusions, short-term memory loss, and
disintegration of language to the point of mutism (Prüss et al.,
2010; Dalmau et al., 2011; Vincent et al., 2011). Therefore,
anti-NMDAR encephalitis is an important diﬀerential diagnosis
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TABLE 5 | Cerebral Magnetic Resonance Imaging (cMRI) and
Electroencephalography (EEG) Abnormalities.
Localization of cMRI abnormalities* (N = 152) Frequency (%)
White matter 26 (17.1%)
Cortical atrophy 11 (7.2%)
Temporal lobe 4 (2.6%)
Frontal lobe 3 (2.0%)
Parietal/ occipital lobe 2 (1.3%)
Cerebellum 1 (0.7%)
Brainstem 1 (0.7%)
Brain’s ventricle abnormalities 5 (3.3%)
Thalamus 3 (2.0%)
Unspecific changes 4 (2.6%)
cMRI abnormalities (absolute) 60 (39.5%)
EEG abnormalities* (N = 175) Frequency (%)
Continuous generalized slow activity 7 (4%)
Continuous regional slow activity 0 (0%)
Intermittent generalized slow activity 32 (18.3%)
Intermittent regional slow activity 14 (8%)
Epileptic pattern 7 (4%)
EEG abnormalities (total) 60 (34.3%)
*Only the predominant cMRI lesion or EEG abnormality is listed for each patient. cMRI,
cerebral MRI.
for catatonic schizophrenia. In the course of the disease, patients
may suﬀer from hypoventilation, seizures, and autonomic
instability (Prüss et al., 2010; Dalmau et al., 2011). The detection
of anti-NMDAR antibodies is clinically important due to the
high eﬃcacy of immunomodulatory therapy options, including
intravenous corticosteroids, plasma exchange, intravenous
immunoglobulins, azathioprine, or monoclonal antibodies (e.g.,
rituximab) (Peery et al., 2012). In our collective, we found
anti-NMDAR-IgG antibody positivity in serum in only one case.
In a retrospective study by Steiner et al. a far higher number
(9.9%) of low-titer anti-NMDA receptor antibodies were found
in schizophrenic patients (Steiner et al., 2013). A recent study
by Hammer et al. again showed a high prevalence of these
antibodies in schizophrenic patients (8.6%) but, interestingly, an
even higher prevalence in healthy controls (10.8%) (Hammer
et al., 2014). Steiner and colleagues have in the meantime
re-analyzed their sample, now also ﬁnding an equal percentage
of anti-NMDAR antibodies in healthy controls (Steiner et al.,
2014). However, in our clinic in Freiburg, we measured only
IgG antibodies, Steiner et al. and Hammer et al. measured also
IgA and IgM antibodies (Steiner et al., 2013; Hammer et al.,
2014). Looking only on IgG-NMDR-antibodies, we found similar
prevalence rates to those of previous studies. In the studies by
Steiner et al. andHammer et al. only the sera of psychotic patients
and controls were analyzed (Steiner et al., 2013; Hammer et al.,
2014), in our study, we mostly analyzed CSF samples. Looking
at the high prevalence rates of NMDAR antibodies in healthy
subjects, it may be assumed that positive antibodies in the serum
probably must be associated with another mechanism, such as
disturbed BBB dysfunction, in NMDAR-antibody carriers to
enter a state of immunological encephalopathy (Hammer et al.,
2014). Therefore, serum measurement and CSF antibody status,
combined with CSF basic diagnostics, might be useful to detect
such constellations.
We also found anti-VGKC complex antibodies in 2.4% of
our collective (three cases). Anti-VGKC complex encephalitis
often leads to limbic encephalopathy and symptoms of seizures,
memory loss, and aﬀective symptoms (Reid et al., 2009; Radja
and Cavanna, 2013). However, there are cases were such patients
at least initially presented with classical psychiatric syndromes,
such as acute schizophreniform disorder (van Elst et al., 2011;
Gnanavel, 2014).
Antineuronal Antibodies against Intracellular
Onconeural Antigens
Interestingly, we also found antineuronal antibodies against
intracellular onconeural antigens in 3.5% of our patients
(Tables 2B, 3; ﬁve cases). In particular, anti-Yo reactivity was
detected in three patients (2.1%). Anti-Yo antibodies target
Purkinje cells of the cerebellum and are the most common reason
for paraneoplastic cerebellar degeneration (Hasadsri et al., 2013;
Stich and Rauer, 2014). However, none of our patients had
cancer. A recent study by Laadhar et al. showed an association
between psychiatric diseases and antibodies against intracellular
neuronal antigens. They described conﬁrmed, well-characterized
antineuronal antibodies (reproducible in a conﬁrmation test) in
ﬁve (anti-Yo in three, anti-Ri in two) of 143 patients, and none
in the control group (Laadhar et al., 2015). Another large study
found anti-Yo antibodies in 0.4% of 1378 schizophrenic patients,
but also in 0.6% of healthy controls (Dahm et al., 2014). It was
previously assumed that these well-characterized antineuronal
antibodies are mostly associated with paraneoplastic neurological
syndromes. Low-titre antibodies without neurological symptoms
are also known in cancer patients. Our results in combination
with the data from Laadhar et al. and Dahm et al. provide
the ﬁrst evidence of the existence of low-titre onconeural
antibodies in psychiatric patients (Dahm et al., 2014; Laadhar
et al., 2015). Otherwise, high percentages in healthy controls
raise the question about the pathophysiological meaning of
such ﬁndings. In any case, positive antibody ﬁndings should
result in organic clariﬁcation. We recently published the case
of a 20-year-old female patient with low-titre anti-Yo positivity
with intrathecal synthesis and fronto-parieto-cerebellar atrophy
in cMRI and a moderate hypometabolism of the cerebellar
hemispheres in the FDG-PET (Endres et al., 2015). Based on
such cases, one might speculate that neuronal dysfunction,
possibly via cytotoxic T-cell activity, might be a diﬀerent
pathogenetic mechanism leading to neuropsychiatric symptoms
in a subgroup of psychotic patients (Kayser et al., 2010).
Alternatively, in this constellation, the intracellular antibodies
may indicate the presence of a cancer that is not yet detectable
with standard diagnostic means. In this constellation, the
psychotic syndrome would function like an early heralding
paraneoplastic syndrome and might be beneﬁcial in that it could
facilitate the early detection of a potentially treatable oncological
condition.
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Steroid Responsive Encephalopathy Associated
with Autoimmune Thyroiditis
In patients with psychotic symptoms and cognitive impairment
in the context of autoimmune thyroiditis, a steroid responsive
encephalopathy with autoimmune thyroiditis (SREAT) should
be considered. For screening, thyroid hormones and particularly
thyroid peroxidase and thyroglobulin antibodies should be
investigated (Castillo et al., 2006). In our study, thyroid
antibodies were elevated in 24.7%, which is remarkably more
than the estimated prevalence in the general population
(Hollowell et al., 2002). In earlier studies, EEG abnormalities were
found in nearly 95% of SREAT patients (most often generalized
slowing). cMRI and CSF diagnostics also added to diagnostic
certainty. In any case, steroid responsivity is the essential feature
for diagnostic assignment (Castillo et al., 2006). Therefore, it is
important to oﬀer steroid treatment in suspect cases, since the
therapeutic success even in long term and classical psychiatric
presentations can be very remarkable.
Psychotic Syndromes—An Immunological
Encephalopathy?
The issue of limbic encephalitis and related immunological
encephalopathies as a possible cause for schizophreniform
or also aﬀective syndromes is still new in psychiatry. Some
authors summarize all antibody associated autoimmune
encephalopathies within the umbrella concept of immunological
encephalopathies and propose a standardized symptomatic
immunomodulatory therapeutic approach for all of these
diseases including anti-VGKC- and anti-NMDAR-encephalitis
as well as SREAT (Friese and Magnus, 2012). Our data
illustrate that systematic diagnostic screening in fact result
in high rates of diverse abnormal immunological signals.
However, the therapeutic implications are still poorly
understood.
Implications for Clinical Diagnostic Assessment
and Therapy
The issue of adapting clinical diagnostic and therapeutic
standards to the advent of concepts of immunological
encephalopathy and limbic encephalitis will most likely be
very controversial. In many—if not in the majority—of
psychiatric clinics, there won’t be diagnostic competence for
doing routine CSF studies. Additionally, many psychotic patients
will not comply with doing CSF studies and in this constellation,
currently, we don’t do such investigations neither. The question
of cost-eﬀectiveness also arises. Does it make sense to diagnose
immunological encephalopathy in a patient with psychological
symptoms when it is unclear how this patient should then be
treated? While such considerations question the rational of
oﬀering CSF studies to all patients with acute psychosis, there
are also many arguments in favor of such a procedure. The
vast majority of our psychotic patients did comply with these
investigations and in fact were actively pursuing this road.
One likely reason is that the disease model of “psychosis as
an inﬂammatory brain process” was easier to accept for these
patients and their families than the concept of schizophrenia. In
quite a few of our immunological encephalopathy patients, the
response to immune therapy was very good and in fact much
better than the response to the classical variant of symptomatic
psychopharmacology. These patients were happy to receive a
more causal therapy than, for example, only taking symptomatic
antipsychotic drugs.
Conclusion
Clinicians must balance the potential beneﬁts of a diagnostic
procedure against its medical risks and costs. With the medical
risk and ﬁnancial costs of doing a CSF study being very low,
and based on our data one has to judge whether it is worthwhile
doing CSF studies in 100 patients in order to detect three with
increased WBC counts, about 40 with some evidence of BBB
disturbance, seven with OCBs, and seven with autoantibodies
against some neuronal cell surface or intracellular antibodies.
Given the potentially devastating course of schizophreniform
syndromes, the authors of this paper feel that our data strongly
point in favor of more comprehensive CSF investigations as
routine procedures in psychotic patients. There is still a very
large demand for research not only in the diagnostic but also in
the linked therapeutic dimension. In case CSF ﬁndings like ours
were clearly linked to beneﬁcial responses to immunomodulatory
treatments, this obviously would change the diagnostic and
therapeutic reality in psychiatry in a dramatic way.
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